

Recurrent Anaplastic Astrocytoma					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Bota	Jennifer	UCI 16-22: A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemo	Enzyme ornithine decarboxylase (ODC) inhibitor	First AA tumor progression or recurrence ≤ 3 months prior to randomization based on MRI criteria for tumor progression. Completion of EBRT ≥ 6 months prior to randomization.	Open to Accrual
Newly Diagnosed Glioblastoma					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Bota	Ricardo	UCI 17-88: Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetininate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects	Improving the hypoxic tumor microenvironment	Newly Diagnosed GBM The only surgical consideration is biopsy Measurable (>10mm x 10mm) contrast enhancing disease	Open to Accrual
Bota	Jinah	UCI 17-115: Phase II trial of AV-GBM-1 (autologous dendritic cells loaded with autologous tumor associated antigens) as an adjunctive therapy following primary surgery plus concurrent chemoradiation in patients with newly diagnosed glioblastoma	autologous dendritic cells loaded with autologous tumor associated antigens and admixed with adjuvant GM-CSF prior to injection	Newly diagnosed GBM patients scheduled for surgical resection at UC Irvine	Open to Accrual
Recurrent Glioblastoma					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Kong	Jennifer	UCI 17-35: A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion Combination with Bevacizumab (Bev) versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy	Synthetic peptide vaccine	First recurrence of GBM only Avastin Naïve Measurable disease	Open to Accrual
Bota	Manisha	UCI 13-14: A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of (ERC1671/ GM-CSF / Cyclophosphamide) + Bevacizumab versus (Placebo Injection / Placebo pill) + Bevacizumab in the Treatment of Recurrent/Progressive, Bevacizumab Naïve Glioblast	ERC1671: Course of vaccines containing irradiated whole and lysed primary tumor cells from allogeneic and autologous GBM patients	First/Second recurrence of GBM Avastin Naïve	Suspended
Bota	Jennifer	UCI 14-58: Phase 1, Multi-Center, Open-Label, Dose-Escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-Naïve Subjects with WHO Grade IV Malignant Glioma Followed by Phase 2 Studies of Single Agent Marizomib and Combination Marizomib	Proteasome inhibits	First/Second recurrence of GBM Avastin Naïve	Open to Accrual (wait list)

Newly Diagnosed Meningioma					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Kong	Jennifer	NRG BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma	Radiation Therapy	Newly diagnosed unifocal intracranial meningioma Gross totally resected Central Pathology Review for confirmation of histology	Open to Accrual
Recurrent Meningioma					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Bota	Mehir	A071401: Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations	SMO competitive antagonist, FAK inhibitor	Central pathology review for SMO/Ptch1/NF2 mutation Progressive or residual disease in Meningioma Measurable disease per RANO criteria	Temporarily suspended
Craniopharyngiomas					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Bota	Mehir	Alliance A071601: Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas	BRAF/MEK inhibitors	Central pathology review with positive BRAF V600E mutation by IHC Measurable disease No prior treatment with BRAF or MEK inhibitors	Open to Accrual
CNS Metastases					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Bota	Mehir	UCI 16-74: A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Ta	Topoisomerase-I inhibitor	Histologically-confirmed carcinoma of the breast Measurable or non-measurable disease History of brain metastases that are non-progressing and that must have been previously treated with either combination therapy or surgery \geq 14 days prior to randomization, or single-agent modality	Open to Accrual
Rare Cancers					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Bota	Manisha	ECOG EAY131: Molecular Analysis for Therapy Choice (MATCH)	Treatment based on mutations	Positive for specific mutations	Open to Accrual
Bota	Mehir	SWOG S1609: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Immunotherapy	Recurrent disease - Rare cancer Paraganglioma	Open to Accrual

Supportive Care/Diagnostic					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Bota	Mehir	ALLIANCE A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma	CNS stimulant	Diagnosed with glioblastoma, gliosarcoma, small cell or large cell glioblastoma, glioblastoma with oligo features, glioblastoma with primitive neuroectodermal tumor-like components (GBM-PNET) features, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma who are clinically stable and have completed radiation therapy ≥ 6 score on the worst fatigue question of the BFI (Brief Fatigue Inventory)	Open to Accrual
Chow	Jennifer	ECOG EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma	Imaging trial	Recurrent glioblastoma or gliosarcoma Avastin Naïve with plan to administer Avastin either as single therapy or in conjunction with other chemotherapeutic regimens	Open to Accrual